10 Best Multibagger Stocks To Buy Heading into 2025

6. Rezolute, Inc. (NASDAQ:RZLT)

1-Year Share Price Performance: ~573%

2-Year Share Price Performance: ~265%

Average Price Target Upside: 126.48%

Rezolute, Inc. (NASDAQ:RZLT) is a late-stage rare disease company focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, ersodetug, is an intravenous human monoclonal antibody designed to treat hypoglycemia caused by various forms of HI. The antibody works by binding to a unique site on the insulin receptor, reducing insulin’s effect and helping restore glucose balance.

Rezolute (NASDAQ:RZLT) provided fiscal Q1 2025 results and business updates on November 7. The company’s focus for 2025 will be on advancing its Phase 3 programs for congenital and tumor hypoglycemia (HI) patients. CEO Nevan Elam highlighted the progress made in enrolling patients for the sunRIZE trial, a global Phase 3 study for ersodetug in congenital HI, and the upcoming U.S. enrollment expected in early 2025.

Topline results for the congenital HI study are expected in the second half of 2025. For tumor HI, the Phase 3 study is progressing with enrollment expected in 2025, and topline results anticipated in 2026.

As of September 30, 2024, Rezolute (NASDAQ:RZLT) reported $117.8 million in cash, cash equivalents, and marketable securities, down from $127.1 million on June 30, 2024. On November 8, The Fly reported that JMP Securities analyst Jason Butler increased the price target for the company to $8 from $7 while maintaining an Outperform rating on the stock after the company’s Q1 results.

The analyst noted that the Phase 3 trial for ersodetug in congenital hyperinsulinism is progressing with patient enrollment, and the results are expected to be released in the second half of 2025.